Mode
Text Size
Log in / Sign up
N/A N=103

Mechanisms of Chronic Kidney Disease (CKD)-Induced Foam Cell Formation

Chronic Kidney Disease · Cardiovascular Disease

Enrolled (actual)
103
Serious AEs
0.0%
Results posted
Apr 2017
Primary outcome: Primary: In Vitro Lipoprotein Functions — 20.8; 26.5 Percentage of cholesterol content

Study Design & Population

Study type
Observational
Phase
N/A
Interventions
Age
Adult, Older Adult · 18+ yrs
Sex
All
Sponsor
Vanderbilt University Medical Center
Primary completion
Apr 2015

Outcome Measures

OutcomeResultp-value
PRIMARY
In Vitro Lipoprotein Functions
20.8; 26.5

Summary

There is currently little understanding of macrophage cholesterol homeostasis and foam cell formation across the spectrum of CKD. We hypothesize that an inverse relationship exist between the severity of CKD and processes underlying foam cell formation, and that the relationship becomes independent of serum lipoprotein levels as renal function declines. We propose to systematically examine scavenger receptors and cholesterol uptake as well as cholesterol transporters and efflux mechanisms in individuals with normal renal function, patients with moderate CKD. We further propose to determine if processed contributing to foam cell formation are related to the plasma lipid profile and if the relationship is modified by co-morbidities, such as diabetes, obesity, systemic inflammation which are common in this population and directly influence vascular integrity. These data will be critically important to understand when the abnormality starts and will provide crucial information.

Eligibility Criteria

Inclusion Criteria

Patients with moderate degree of CKD, or patients with advanced CKD or control subjects with intact kidney function

Male or female

All ethnic groups

≥ 18 years and have signed informed consent

Exclusion Criteria

Pregnancy and current smoking

BMI > 45

Rheumatoid arthritis and systemic lupus erythematosus

History of active or chronic hepatitis B, history of active or chronic hepatitis C, human immunodeficiency virus (HIV)

For moderate CKD subjects: nephrotic syndrome

For control subjects: nephrotic syndrome, patients with estimated GFR < 60 mL/min/1.73 m^2, or proteinuria

View full record on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov (NCT01671605). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.

Back to search